Heart failure & cardiomyopathies

Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score–Matched Analysis of the TOPCAT Americas Trial

EuropacePublished Post-hoc analysis of the TOPCAT Americas randomised trial

Authors' conclusion

Prevalent AF can be an independent risk factor for adverse CV outcomes by its selective association with worsening HF, HFH, and PFD in HFpEF. Prevalent AF was not associated with excess sudden death risk in HFpEF. Atrial fibrillation was also associated with HF progression in early symptomatic HFpEF and PFD in advanced HFpEF.

Study context

Population
Patients with HFpEF in the TOPCAT Americas trialPropensity score-matched (PSM) cohorts
Comparison
Prevalent atrial fibrillation (AF) vs no AF
  • Any AFn = 584
  • AF on electrocardiogram (ECG)n = 418
Primary endpoint
Cardiovascular (CV) death, cause-specific mortality and HF morbidity
Follow-up
Mean 2.9 years
Methodological detailspropensity-score matched
  • Propensity-score matched

Primary result

As reported in the abstract

Hazard ratio (95% CI)P value
Any AFvs No AFCV hospitalization
1.33(1.11–1.61)
P = 0.003
Any AFvs No AFHF hospitalization
1.44(1.12–1.86)
P = 0.004
Any AFvs No AFpump failure death
1.95(1.05–3.62)
P = 0.035
Any AFvs No AFHF progression NYHA I/II to III/IV
1.30(1.04–1.62)
P = 0.02
AF on ECGvs Sinus rhythmCV death
1.46(1.02–2.09)
P = 0.039
AF on ECGvs Sinus rhythmpump failure death
2.21(1.11–4.40)
P = 0.024
AF on ECGvs Sinus rhythmCV hospitalization
1.37(1.09–1.72)
P = 0.006
AF on ECGvs Sinus rhythmHF hospitalization
1.65(1.22–2.23)
P = 0.001

Further findings

Pump failure death in New York Heart Association (NYHA) III/IV heart failure (HF) (subgroup)

Both Any AF and AF on ECG associated with pump failure death

Original publication

Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score–Matched Analysis of the TOPCAT Americas Trial. Europace. Published 20 April 2023. doi:10.1093/europace/euad095

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.